Home » Topics » Disease categories and therapies » Respiratory

Respiratory
RSS

The Cystic Fibrosis Foundation funds drug discovery program at Aurora

Sep. 14, 1999

Alinastine: pharmacological properties indicate benefit in seasonal allergic rhinoconjunctivitis

Sep. 14, 1999

VUF-K-8788: new antiallergic agent characterized in experimental studies

Sep. 13, 1999

Protease-inhibitory cephams and cephems and their use patented by Pliva

Sep. 13, 1999

Phthalazinones synthesized at Byk Gulden specifically inhibit PDE4

Sep. 10, 1999

Agents for allergic diseases in development by Dainippon Ink & Chemicals

Sep. 10, 1999

German collaboration yields new inhibitors of human tryptase

Sep. 7, 1999

Glaxo Wellcome patents improved adenosine A2A receptor agonists as antiinflammatory agents

Sep. 6, 1999

HMR and Sepracor resolve issues relating to fexofenadine

Sep. 3, 1999

New phenylethanolamine bronchodilators synthesized at Chinese university

Sep. 2, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 24, 2026.
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
AACR 2026: The age of agentic AI in oncology
BioWorld Science
New Approach Methodologies (NAMs) for drug development are transforming biomedical research by replacing or complementing animal models. More than 90% of...
In the clinic for April 21, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Abbott, Agenus, Astrazeneca, Briacell, Clearmind, Greenwich, Intodna,...